Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions (e.g., kits) for the identification of subjects with misfolded proteins in their urine. For example, methods and compositions for determining that a urine sample from a pregnant woman contains or does not contain misfolded are provided. In some embodiments, the presence of misfolded proteins in a urine sample from a pregnant woman is an indication of preeclampsia.

Abstract: This document provides materials and methods for identifying and quantifying AIM polypeptides in a sample using mass spectrometry techniques. For example, methods of using mass spectrometry to identify and quantify AIM polypeptides in a serum sample are provided. In some cases, quantification of AIM polypeptides can be used to diagnose and/or treat patients having a disease or disorder characterized by altered (e.g., increased or decreased) AIM polypeptide levels.

Abstract: A machine learning model is generated for drug efficacy prediction in treatment of genetic disease from a dataset correlating gene expression data for disease-cell samples with drug efficacy values for the samples. Bias weights are stored that correspond to respective genes in the samples. Each bias weight is dependent on predetermined relevance of the respective gene to drug efficacy. The model is generated by processing the dataset via a tree ensemble method wherein decision trees are grown with splits corresponding to respective genes in the samples. The gene for each split is chosen from a respective subset of the genes, and genes are selected for inclusion in this subset with respective probabilities dependent on the corresponding bias weights. The model is stored, and can be applied to gene expression data measured for a patient to obtain a personalized drug efficacy prediction for devising a personalized course of treatment.

Abstract: Provided are methods of detecting the presence or amount of a vitamin D metabolite in a sample using mass spectrometry. The methods generally directed to ionizing a vitamin D metabolite in a sample and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample. Also provided are methods to detect the presence or amount of two or more vitamin D metabolites in a single assay.

Abstract: An immunochromatographic test piece is provided containing a control line detection reagent that is not affected by the concentration of an analyte to be detected. The immunochromatographic test piece is for quantifying an analyte in a biological sample, and includes (a) a conjugation pad impregnated with a detection reagent that specifically binds to the analyte, and a control line detection reagent; and (b) a porous membrane pad on which an antibody for capturing the analyte is immobilized upstream, and an antibody for capturing specifically the control line detection reagent is immobilized downstream.

Abstract: This disclosure provides systems and methods for sequencing nucleic acids using nucleotide analogues and translocation of tags from incorporated nucleotide analogues through a nanopore. In aspects, this disclosure is related to composition, method, and system for sequencing a nucleic acid using tag molecules and detection of translocation through a nanopore of tags released from incorporation of the molecule.

Abstract: Methods and apparatus providing for the isolation of an unknown mutation from a sample comprising wild type nucleic acids and mutated nucleic acids through the application of time-varying driving fields and periodically varying mobility-altering fields to the sample within in an affinity matrix.

Abstract: An RNA tagging system for visualization of single mRNA molecules based on a MSB-MCP system, as well as methods of use.

Abstract: The invention provides barcode libraries and methods of making and using them including obtaining a plurality of nucleic acid constructs in which each construct comprises a unique N-mer and a functional N-mer and segregating the constructs into a fluid compartments such that each compartment contains one or more copies of a unique construct. The invention further provides methods for digital PCR and for use of barcode libraries in digital PCR.

Abstract: Disclosed herein are antibodies against ENPP3 and uses thereof, specifically monoclonal antibodies against ENPP3, bispecific antibodies against ENPP3 and CD3, nucleic acids including nucleotide sequences encoding the antibodies, vectors including the nucleic acids, and host cell including the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and conjugates including the antibodies, and therapeutic methods for using the antibodies.

Abstract: Described herein are isolated regulatory peptides of protein kinase C, chimeric peptides thereof, and their variants. Use of the described peptides, in compositions and methods for treatment of cellular proliferation pathologies is also described.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to cell free protein manufacturing, and more particularly, for integrating machine learning into a portable cell-free bioprocessing system for producing proteins with increased and consistent purity, potency and quality wherein such proteins are prepared on-demand and for point-of-care delivery.

Abstract: Method, apparatus, and computer program product are provided for anonymized diagnosis using lateral flow assays. In some embodiments, a test card includes one or more lateral flow assay (LFA) with one or more test patterns (e.g., full line, partial line, dot), one or more dummy patterns, and one or more control patterns. To visually encode LFA results, at manufacture, one or more lines/dots containing true results of the LFA(s) each has a position mixed with other “dummy” lines/dots, in randomized position patterns selected from among a plurality of possible position patterns. An optical machine-readable representation of data (e.g., QR code) is attached to the test card and encodes test card identification information (e.g., lot number, serial number, test type) associated with the test card. In some embodiments, a passcode card having a scrapeable coating that conceals a passcode associated with the test card is removably attached to the test card.

Abstract: A method including: providing a sample with M components to be labeled, where M>2; labeling the components with N stains, where N<M so that at least two components are labeled with a common stain; obtaining a set of spectral images of the sample; classifying different parts of the sample into respective classes that distinguish the commonly stained components based on the set of spectral images; and determining relative amounts of multiple ones of the M components in different regions of the sample. Related apparatus are also disclosed.

Abstract: An analysis method for detecting an amount of a substance by irradiating an analysis chip containing the substance and detecting a quantity of light output from the analysis chip. The analysis method including irradiating an incident surface of the analysis chip and another surface adjacent to the incident surface with detection light while changing a relative position of the detection light with respect to the analysis chip, detecting reflected light from the incident surface of the analysis chip, and acquiring information on a position of the analysis chip from a relationship between a quantity of the reflected light detected and the relative position. The analysis method determines if the analysis chip is abnormal when a quantity of target reflected light is equal to or lower than a predetermined light quantity.

Abstract: The present invention relates to a background blocking concept for use in time-resolved fluorometry binding assays. More particular, the invention relates to a binding assay and a kit involving the use of the same or similar chelating ligand in lanthanide chelate-labelled analyte-specific biomolecules and as or in a background blocking agent.

Abstract: This disclosure presents inventions for ionization, for example, for use in mass spectrometer devices and methods. In an embodiment, a device is provided for introduction of pulses of a first carrier gas into an ionization chamber and introduction of a second carrier gas into the ionization chamber. Electrodes in the chamber ionize the carrier gas and direct the ionized gas toward a sample for analysis. The second carrier gas can either assist in washing out the first carrier gas or may become ionized along with the first carrier gas to improve ionization of an analyte. In an embodiment, a method for producing ionized carrier gasses is provided.

Abstract: A ligand includes a molecular skeleton, a first coordinating group connected to the molecular skeleton, at least one initial group connected to the molecular skeleton, and a protecting group connected to an end of each initial group away from the molecular skeleton. Each initial group is capable of forming a second coordinating group after deprotection.

Abstract: Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

Abstract: The present invention relates to detecting serum anti-FadA antibodies in test samples from a patient. Additionally, aspects of the present invention provide the basis for detection of serum anti-FadA antibody levels from test samples and correlation with various conditions of clinical relevance.

Abstract: A method for providing nutritional supplement information for a subject is proposed, including a sequence of steps in given order and repeated at least once after a time span of at least 2 days or one week for adapting the provided nutritional information: A) taking a sample from the subject; B) analyzing said sample to determine the nutritional status; C) based on the results calculation of nutritional supplements to improve the nutritional status; D) providing individualized nutritional supplement information. This sequence involves the prediction of at least one initial characteristics matrix and multiplication of this matrix weighted with factors, with an initial recommendation vector for the calculation of a target profile vector after a given first time interval from the profile vector as determined in step B), and in each following cycle adaptation by adapting at least one of the characteristics matrix and the weighting factors.

Abstract: Provided are an additive and a surface treatment agent capable of suppressing agglutination of latex particles contained in a reagent for a latex agglutination reaction during storage of the reagent although a synthetic polymer is contained as an active component. An additive is to be added to latex particles used in a reagent for a latex agglutination reaction. The latex particles have not been subjected to blocking treatment. The additive includes a polymer containing more than 60% by mass and 99% by mass or less of hydrophilic repeating units (A) relative to all repeating units and 1% by mass or more and less than 40% by mass of hydrophobic repeating units (B) relative to all repeating units, and having a weight average molecular weight of 3,000 or more.

Abstract: This invention provides reagents and methods for diagnosing renal disease. Differential levels of inosine metabolite, and proteins: apolipoprotein C-I, apolipoprotein C-II, fibrinogen alpha chain, or fibrinogen A-alpha chain, kininogen, Inter-Alpha Inhibitor H4 (ITIH4), keratin Type I cytoskeletol 10 cystatin A, cystatin B and other polypeptides and fragments thereof provide biomarkers of renal disease and are described herein.

Abstract: Sialic acid recognizing-affinity reagents engineered from the neuraminidase NanB have lectin-like properties and defined specificities for sialic acid.

Abstract: Beads with functionalized material applied to them are exposed to an acoustic field to trap or pass the beads. The beads may include or be free of ferro magnetic material. The beads may be biocompatible or biodegradable for a host. The size of the beads may vary over a range, and/or be heterogenous or homogenous. The composition of the beads may include high, neutral or low acoustic contrast material. The chemistry of the functionalized material may be compatible with existing processes.

Abstract: Provided are devices and methods to detect the presence of volatile organic compounds related to the presence of a disease state in a biological sample. The devices may include a detection moiety such as a polynucleotide in electronic communication with a semiconductor such as graphene or a carbon nanotube.

Abstract: A method for producing a laminate, the method comprising at least a pretreatment step of pretreating a surface of a substrate made of a plastic film by reactive ion etching so that the maximum displacement of the substrate surface measured by local thermal analysis is 300 nm or more, and a lamination step of laminating a thermoplastic resin layer made of a material different from that of the substrate on the pretreated surface of the substrate; wherein the plastic film is a polyethylene terephthalate film.

Abstract: Provided is a method for analyzing a protein-containing sample. The method comprises (1) dissolving a probe capable of non-specifically interacting with a plurality of proteins in a plurality of solvents having different ionic strengths and/or pH levels; (2) adding a protein-containing sample to a plurality of probe solutions prepared in the step (1), thereby the proteins in the sample and the probe are interacted non-specifically; (3) measuring the fluorescence intensities of the plurality of probe solutions to which the protein-containing sample was added in the step (2); and (4) comparing the pattern of fluorescence intensities obtained in the step (3) with the pattern of fluorescence intensities obtained from a reference sample.

Abstract: Provided is a reagent for assaying a thrombin-antithrombin complex (TAT) in a blood sample from a subject by latex agglutination assay. The reagent includes a polycation. As a result, TAT complexes can be precisely assayed while circumventing the effect of heparin.

Abstract: Disclosed herein are, inter alia, methods and compositions useful for detecting and/or quantifying host cell proteins during the production of a product, e.g., a recombinant protein, e.g., an antibody.

Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent anti-tumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.

Abstract: Provided herein are non-naturally occurring polypeptides comprising a sequence of a fragment of a collagen and recombinant cells containing heterologous nucleic acid sequences encoding the non-naturally occurring polypeptides. Further provided herein are animal-free methods of generating and purifying such non-naturally occurring polypeptides using microorganisms, preferably from bacterial cells.

Abstract: The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent anti-tumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus.

Abstract: Provided herein are surface enhanced Raman scattering (SERS)-active reagents and methods for detecting one or more analyte in a sample. Said SERS-active reagents are adaptable, sensitive, and easy-to-use in the diagnosis of infectious diseases in a patient, or the detection of toxins, bacteria, viruses, pathogens, hormones, cytokines, antigens, antibodies or illicit drugs in a biological sample. Such methods may be handled by police, soldiers, or health care workers in the field, and do not require specialized training.

Abstract: Kits containing a multiplexed chemiluminescent detection system and microfluidics devices and methods for detecting the presence and/or concentration of biotin and at least one target analyte in a sample are disclosed. The kits, microfluidics devices, and methods utilize singlet oxygen-activatable chemiluminescent compounds in combination with two or more fluorescent molecules that emit light at different wavelengths.

Abstract: The invention relates generally to devices, systems, compositions, and methods for the detection of oligonucleotides, nucleic acids, antigens, antibodies, peptides, proteins, and non-biological molecules.

Abstract: A secure assay device is disclosed herein that provides: an assay or a test device that provides at least one result, wherein the assay or test device comprises at least one surface which exhibits optical change in response to at least one target particle, at least one marker or a combination thereof; and at least one multi-layer coating that at least partially covers the assay membrane, the assay device or a combination thereof, wherein the multi-layer coating blocks or impairs the user visualization of the optical change, the at least one result or a combination thereof. A secure reader and method of utilizing the secure assay device and secure reader are disclosed herein.

Abstract: Some embodiments of the disclosure provide a time-resolved fluorescent immunochromatographic test strip for detecting paclitaxel drugs as well as a preparation method and application thereof. In some embodiments, the test strip includes a test paper and a sample diluent. The test paper includes a bottom plate, a sample absorption pad, a fluorescent microsphere pad, a bonding pad, and an absorbent pad. The sample absorption pad, the fluorescent microsphere pad, the bonding pad, and the absorbent pad are sequentially overlapped on the bottom plate. The fluorescent microsphere pad is sprayed with a fluorescent microsphere-labeled anti-paclitaxel monoclonal antibody. A detection area and a quality control area are immobilized on the bonding pad. The detection area is sprayed with a paclitaxel hapten-carrier protein conjugate. The quality control area is sprayed with a goat anti mouse antibody.

Abstract: Provided are a biomarker for evaluating a cerebral A? accumulation state using an amyloid precursor protein (APP)-derived peptide in a living body-derived sample as an index, and a method for analysis thereof. A living body-derived sample derived from a test subject is measured, and at least one ratio selected from the group consisting of APP669-711/APP672-713 (A?1-42); APP672-709 (A?1-38)/APP672-713 (A?1-42); APP674-711 (A?3-40)/APP672-713 (A?1-42); APP672-710 (A?1-39)/APP672-713 (A?1-42); APP672-711 (A?1-40)/APP672-713 (A?1-42); and APP672-711 (OxA?1-40)/APP672-713 (A?1-42) is calculated, and when each of the ratios of the test subject is higher than each of standard levels which are ratios of a person having normal cognitive function NC? who is negative for cerebral A? accumulation, an accumulation amount of cerebral A? of the test subject is determined as larger than an accumulation amount of cerebral A? of the person having normal cognitive function NC?.

Abstract: An inspection chip according to the present invention is an inspection chip for stirring liquid by a circular movement of a bottom surface end, including a well main body for accommodating the liquid and a side wall member arranged on a side surface of the well main body. The bottom surface end has a bottom surface structure in contact with a rotating member for allowing the bottom surface end to perform the circular movement in a position leaning from a center line of the well main body toward the side wall member.

Abstract: The present invention provides compounds used in the synthesis of chemiluminescent acridinium compounds and methods of producing these compounds. Specifically, methods are provided for the N-alkylation of acridan compounds using alkylating reagents. Typically, these alkylating reagents comprise a protected sulfonate group protected with an acid-labile protecting group.

Abstract: A testing system includes a well cover portion, a sensor portion extending from the well cover portion, a sensing surface disposed on the sensor portion, a conducting wire extending through the sensor portion and contacting the sensing surface, a transducer connected to the conducting wire, and a reference electrode extending through the well cover portion.

Abstract: A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of PAI-2 and sTNFR1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing GDM.

Abstract: Provided herein is a small molecule delivery system with illumination-induced small molecule release based on the binary combination of charged liposomes containing small molecules and oppositely charged conjugates of a peptide with a photosensitizer attached to one end of peptide chain, providing binding to liposomes and their permeabilization upon light illumination.

Abstract: A device for detecting cotinine includes (a) a film that includes a plurality of molecularly-imprinted-polymer (MIP) coated conductive nanoparticles having specific affinity for binding with cotinine, and (b) two electrodes in contact with the film for passing electrical current through the film to detect binding with cotinine as a change in electrical conductivity of the film. A MIP coated conductive nanoparticle for detecting cotinine includes (a) a conductive nanoparticle, (b) a silicon dioxide coating formed on the conductive nanoparticle and forming a first shell around the conductive nanoparticle, and (c) an MIP coating formed on the silicon dioxide coating and forming the second shell, wherein the MIP coating includes a polymer molecularly imprinted with cotinine to provide specific affinity for binding of cotinine to the MIP coated conductive nanoparticle such that the cotinine is detectable as a change in electrical conductivity of the MIP coated conductive nanoparticle.

Abstract: Provided are novel methods for screening and testing for pathogens in food, water, and bodily fluids using methods that are faster to complete than conventional methods of culturing and plating that require lengthy times in properly equipped labs. The invention utilizes specific, rapid and sensitive optical detection to capture small concentrations of the target bacteria and render them amenable for detection with various specific synthesis binding agents approaches. The technique merges capture and detection steps with quantification unit suitable to provide results in a relatively shorter time current detection methods.

Abstract: Disclosed is an antibody which binds to a symmetrically dimethylated arginine analyte that can be used to detect a symmetrically dimethylated arginine analyte in a sample, such as in a homogeneous enzyme immunoassay method.

Abstract: The invention provides populations of isolated peptides useful for the detection of antibodies that bind to Anaplasma antigens. The peptide populations comprise peptides derived from immunogenic fragments of the Anaplasma Outer Membrane Protein proteins. The invention also provides devices, methods, and kits comprising the populations of isolated peptides useful for the detection of antibodies that bind to Anaplasma antigens and the diagnosis of anaplasmosis. Methods of identifying the particular Anaplasma species infecting a subject using the peptide populations of the invention are also disclosed.

Abstract: The invention discloses a detergent-compatible protein assay method, composition and kit based on bio-conjugation reaction between protein and Meldrum's acid activated furfural. The method includes adding MAF in dimethyl sulfoxide (DMSO) to a protein sample solution. The amine functionalities present on the amino acid residues reacts with the MAF instantaneously at room temperature to yield deep purple colored solutions of the corresponding conjugated proteins. The reagent composition added to protein may be in the range of 90-450 mM. The intensities of purple colored solutions were proportional to the protein concentration captured by spectrophotometric measurements. The assay is sensitive in the range of 0.125-15 mg/mL, is compatible with commonly used detergents and reducing agents in protein solutions and may be employed for estimation of protein samples in the presence of detergents and reducing agents.